Rare-variant association study unveils the Achilles’ heel for HCC

Abstract

In this issue of Cell Genomics, Wang, Liu, Zuo, Wang, etal.1 investigate rare variants in hepatocellular carcinoma (HCC) by performing the first rare-variant association study (RVAS) in a Chinese population cohort. It uncovers BRCAness phenotypes associated with the NRDE2-p.N377I variant, suggesting PARP inhibitors as a promising therapeutic approach for certain HCC patients.